| Actelion Fibrosis Drug Doesn't Meet Key Endpoint |
 |
 |
 |
| Monday, 01 March 2010 10:54 |
|
Actelion Ltd today announced the initial results of BUILD-3, a clinical study evaluating the safety and efficacy of Bosentan in patients suffering from idiopathic pulmonary fibrosis. While there was a consistent trend in favour of Bosentan, the primary endpoint, reduction in morbidity/mortality, was not met (p=0.21). The well characterized safety profile of Bosentan was confirmed.
Bosentan is an orally available dual Endothelin receptor antagonist, already approved worldwide for the treatment of pulmonary arterial hypertension under the brand name Tracleer. In the European Union and in other territories, Tracleer is also approved for the reduction of new digital ulcers in patients with Systemic Scleroderma. Jean-Paul Clozel, M.D. and Chief Executive Officer of Actelion commented: "We are naturally disappointed with this outcome. While in BUILD-3 there is a consistent trend in favour of Bosentan, these findings do not support initiating regulatory proceedings." Jean-Paul Clozel continued: "We remain convinced that Endothelin receptors are important targets for potential future treatments in this poorly understood and rapidly progressing form of pulmonary fibrosis. The results of BUILD-3 suggest that a more complete blockade of both endothelin receptors - as potentially achieved with macitentan - might be needed." The 150 patient exploratory studies with Actelion's highly potent, tissue-targeting Endothelin receptor antagonist, macitentan, is currently enrolling patients with idiopathic pulmonary fibrosis. The study is expected to be fully enrolled later this year and report data in second half of 2011. Sources: PR Inside, MarketWatch |
More articles :
» The Clinical Relevance of Autoantibodies in Scleroderma
Khanh T Ho and John D ReveillePublished: 12 February 2003Arthritis Res Ther 2003, 5:80-93 (DOI 10.1186/ar628)© 2003 BioMed Central Ltd (Print ISSN 1478-6354; Online ISSN 1478-6362)Scleroderma (systemic sclerosis) is associated with several...
» Xerostomia one of the Sjögren’s Syndrome Symptoms
“The American Health Institute spent $8 million for a research diagnosis of Sjögren syndrome in several countries as an important disease with high impact on society,” he told The Capital Dr. Ricardo Bazet, ophthalmologist, director of Rosario...
» Important Information On Flaxseed And Flaxseed Oil
Flaxseed, called linseed in some countries, is a good source of dietary fiber, , and . Each of these components may contribute to the health effects of eating flaxseed, but flaxseed oil contains no fiber and very little lignan. In addition to its...
» Grant To Fund Study Of Possible Links Between Water Pollution, Disease
Arkansas Children’s Hospital Research Institute scientists have been awarded a $997,000 grant to study the relationship between a common pollutant in water systems and the increase in autoimmune disease. The award was announced yesterday by the...
» Primary and Secondary Pulmonary Hypertension
Pulmonary hypertension is divided into two main types. First is primary pulmonary hypertension which is not caused by any other disease or condition and the second is secondary pulmonary hypertension which is caused by another underlying condition....
» PUVA Therapy In The Treatment of Localized Scleroderma
In localized , disease activity would tend to stop spontaneously over time. Treatment is important to reduce disabilities caused by the active phases of disease. According to , there are three treatments used in the treatment of localized...